"WALL STREET CORNER"
BY WALLSTREETCORNER.COM, INC.
www.WallStreetCorner.com
Corporate Profile
CytoCore, Inc.
Over $40 million is Invested in its Technology
New investment $ makes Turn-Around Virtually Complete
Uterine Cancer Screen Product Unique, Huge Market
Essentials
Business:
Exchange:
Symbol:
Price (Close 5/1/2006):
52-Week Range:
Average Volume (3 Mos.):
Market Cap (@ 5/1//2006):
Shares Authorized:
Approx. Shares Issued (fully diluted):
Approx. Float:
Bio-molecular Cancer Screening
OTC BB
MCDG
$0.21
$0.02 - $0.23
562,914
$54.6 million
300 million
260 million
180 million shares
Approx. Float (active):
40-50 million shares
Our Comment
Larry Oakley has been covering the progress of CytoCore (MCDG), formerly Molecular
Diagnostics, Inc., in editorials since July 2003. At the time of his 10/10/2005 editorial, MCDG
was trading at $0.081. Its present price of $0.21 represents a gain of 159% in the last seven
months. That's just the beginning of its move in our opinion.
Larry's interest was sparked because of the quality of MCDG's technology in cervical and
endometrial cancer detection. Fascinating & useful science. Unfortunately, as often happens
with early-stage companies, the founder who has the vision & persistence to assemble a
portfolio of quality technology is not the right person to successfully move the company
forward. This is what happened at MCDG. The Company began its turn around efforts in
earnest in August of 2005 when a group of long term investors stepped in to manage the
company, and has now virtually completed a very successful restructuring and turn-around.
What CytoCore Does
CytoCore develops cost-effective cancer screening system for all forms of Uterine Cancer.
They can be utilized in a laboratory or at the point-of-care. They assist in the early detection
of cervical and endometrial cancers. The InPath™ System is being developed to provide
medical practitioners with a highly accurate, cervical and endometrial cancer screening
system with unique treatment options that can be integrated into existing medical models or
at the point-of-care.
CytoCore's Unique Position
CytoCore is in a unique position to revolutionize women’s reproductive healthcare,
specifically cervical & uterine cancer screening & diagnostics, on a global scale through its
revolutionary InPath™ System. Based upon a revolutionary new bio-marker (P2X7) which is
proving to be highly accurate in identifying all forms of Uterine cancers and the application of
proteomic (Protein) detection technology, the InPath™ System is designed to detect, at the
earliest possible stage, cancer & cancer-related diseases of the cervix & uterus. The System is
designed so that when fully developed, the exam & the test result could be produced for the
physician at the Point of Service within 15-30 minutes. The System may be used in a
laboratory, clinic, or doctor's office. The P2X7 bio-marker is now being (successfully) tested
as a cancer screening technology which can identify cancer cells for all forms of epithelial
(skin) cancers including skin, lung, and prostrate cancers.
CytoCore’s InPath™ System
The InPath™ System is the only fully integrated screening, diagnostic, & treatment system
for the various forms of cervical & endometrial cancers. It will offer the physician state-ofthe-art bio-molecular screening, diagnostic, & treatment products for coverage for these two
cancer risks for women from the beginning of sexual activity through the end of their days.
CytoCore’s InPath™ System is faster, less expensive, & more specific in identifying those
patients at increased risk of developing a treatable cervical cancer condition than Pap testing
in any form, or HPV DNA testing in any form. InPath™ is designed to provide a complete
testing system for cervical and uterine cancer on a world-wide basis for those locations where
there is no laboratory infrastructure with trained Cyto-technicians.
The System is comprised of the following products, each with significant market potential
& different timelines to market:
The e2 Collector
The current market is 180-190 million Pap tests/yr world-wide – 70-80 million units in the
U.S. The market is gynecologist/OBGYN’s & their patients. The e2 Collector is clinically
proven to provide a better collection of cells more quickly than the traditional spatula/brush
combination. The Collector by design produces a more accurate and more comfortable Pap
test.
The e2 Collector is developed to replace the standard spatula/brush method for collecting
cervical cell samples for the Pap test. The e2 Collector was cleared for marketing & sale by
the FDA in May 2002. Because of its superior sampling characteristics & the market
opportunity for this product, CytoCore intends to bring the e2 Collector to market in the U.S.
as the first product in the InPath System.
The Collector Prototype has been successfully developed. The manufacturer has been
chosen and is about ready to begin the tooling process. It will be ready for manufacturing &
sales within five to six months from start of the tooling process. Management expects the
product to be ready for manufacturing, sales, & distribution starting in Q4 2006. It should
have a 70%+ profit margin. Cash flow breakeven is expected in approximately six months
after sales begin. Because of the rapid adoption of HPV testing (DIGE) and the resulting
increased awareness in women about the Pap tests importance, adoption of the Collector
could be swift. During the summer and early fall of this year, the Company will be developing
its marketing, advertising and distribution strategies for the Collector. This should include
partnering with one or more company’s with distribution strength to these Doctors.
Bio-Molecular ASSAY & AIPS Automated Microscope
The new P2X7 Bio-Marker recently licensed from Dr. Gorodeski and UHC will be used to
screen cancerous cells of the uterus. It is protected by a newly filed patient. Early tests
indicate a great improvement for Pap test accuracy, with the marker upwards of 90%+
accurate vs. 60-70% for today’s Pap test.
The P2X7 will also offer a cancer screen for Endometrial Cancers. At this time, there is no
test anywhere for Endometrial Cancer -- no competition. The U.S. market is as large as 10 –
15 million tests annually. 25% of the target market represents sales in excess of $100million.
Because of there is no screen in the market for Endometrial cancers, the Company plans to
bring the P2X7 to market as quickly as possible as a stand along screen. It should be ready
for trials by late fall this year. There is a large unfilled need for this screening product. This
product is sold to the same market OBGYN Doctors that the e2 Collector addresses.
The AIPS unit, now in its 2nd generation development, serves as an automated testing
platform for the InPath™ System. It reads Marker treated Assay slides quickly &
accurately, identifying abnormal cells for the Cytologist to examine. Product development
should be complete this summer of 2006 when early testing with the new Marker will begin.
The unit could also serve as an automated testing platform for dozens of bio-markers in need
of such a device. It will be ready for partnering by the fall of 2006. An existing contract with
LabCorp is in place using the first generation device.
The P2X7 Marker when combined with the AIPS automated microscope platform will
provide an accurate, fast, cervical cancer screening system that is expected to be ready for
marketing in 2008. These two products together are the heart of the InPath System and in
combination are designed to provide a semi-automated cervical/uterine cancer screen system
for the billion dollar world-wide market opportunity.
A new Drug Delivery System will offer a therapeutic treatment option for mild to
moderate cervical lesions. Approximately 10% of all Pap tests are deemed abnormal.
Abnormal tests are estimated to generate approximately $3BB in expenditures for additional
Pap testing and colposcopy surgery. Surgery is the only option at this time, because there is
no way to therapeutically treat early stage cervical lesions. CytoCore’s drug delivery system
is designed to offer a therapeutic treatment option for the first time. CytoCore’s unique
patent pending Drug Delivery System has no competition & a huge market opportunity. It
will take 24-36 months to complete the development and trials for the device and the various
treatment compounds that will be offered with the patch treatment product.
One of the reasons why we like CytoCore’s business model is because all their products will
be sold to though the same distribution channel….. to the same OBGYN physicians. Once the
sales channels are opened with the e2 Collector, other related new product sales should ramp
quickly, and they should compliment each other with the physician. The marketing leverage
for CytoCore is substantial. This is one of the reasons that we think the company can ramp
up its sales much faster than the typical medical products company.
The Turn-Around
A group of investors were so committed to seeing this technology come to market that they
weathered two changes of management before they finally brought in a team to run the
company who were up to the challenge. Last October, MCDG installed Dr. David Weissberg
as its CEO. He is a successful surgeon/businessman, raised $10million to start a physician
owned HMO (MDNY), & was CEO of the parent company for seven years. He is a major
investor in MCDG with over $1,000,000 invested. His investment is something that we really
like to see.
Since being named CEO, Dr. David Weissberg has increased his holdings in the company
by 1,750,000 shares. When he took over, he said: "I truly believe in the company's technology
& I look forward to communicating with shareholders about the on-going progress being made."
In addition, Robert McCullough Jr, another investor, stepped in as acting CFO and board
member. Bob added 600,000 shares to his holdings during the time this new team took over.
As part of the new management team, Robert McCullough, Jr. was appointed CFO. His
MBA is in finance & he is a CPA. He was an executive at Ernst & Young, & was CFO at two
privately owned health care companies. He has been in the investment business for the last 18
years, & is president of Summitcrest Capital Management. He said: "I am pleased to accept
the CFO position at this time of transition for Molecular Diagnostics. This next period of time is
going to be marked with financial progress as the company enters into the commercialization
phase with one or more of its products. New financing will be required, & with the restructuring
that has taken place & the gathering of new people & resources, I can make a positive
contribution in this area, which will allow Molecular to move development & commercialization
forward with all three of its key products. Like the new CEO David Weissberg, I do not intend to
take a salary until this restructuring with new financing has been successfully completed & there
is a significant improvement in the company's operating results."
On 9/22/2005, MCDG formed a Scientific Medical Advisory Board. The first individual to
join that Board was Dr. George Gorodeski, MD, Ph.D -- an important step for MCDG. Dr.
Gorodeski is a leader in women's reproductive health issues. He is the professor of
reproductive biology, professor of oncology, & professor of physiology & biophysics at Case
Western Reserve University. He was the lead investigator or co-investigator in over 40
different grant sponsored trials, has had 90 papers published in medical & scientific journals,
& has been active with & is the acting president of the North American Menopause Society.
He is the co-inventor of MCDG's e2 Collector. At that time, he said: "I was involved in the
early years with the development of Molecular Diagnostic technology. I believe this company has
a portfolio of world class technology that is essential to addressing women's reproductive health
issues. I am very pleased to see the changes that are occurring with Molecular Diagnostics &
look forward to actively participating in the successful launch of these technologies. I see this
company developing into an organization which can effectively grow new technologies, &
anticipate being able to bring new opportunities to Molecular Diagnostics. As the co-inventor of
the e2 Collector, I am especially interested in this product, & anticipate getting further
collaborative testing done on the collector to demonstrate its superiority, & having a peer review
article published."
Also at that time, Dr. Weissberg commented: "Dr. Gorodeski's participation on our newly
formed Scientific Medical Advisory Board is very exciting to me. Dr. Gorodeski has a long &
distinguished history of innovative & productive scientific work addressing women's health
issues. He represents the caliber of individuals that we intend to gather in support of Molecular's
technology. For Dr. Gorodeski to warmly offer to participate on our Medical Advisory Board
speaks volumes about the man & his commitment to the benefits of this technology getting into
widespread commercial use. We are looking forward to rebuilding Molecular's close working
relationship with Case Western Reserve University & their outstanding medical scientific team."
On 3/30/2006, CytoCore added to its team. It c. announced that Dr. Steven Waggoner will
be joining the Company’s Medical Advisory Board. Dr. Waggoner is Chief, Division of
Gynecologic Oncology, at University Hospitals of Cleveland; Vice-Chairman of Clinical
Affairs, Department of Obstetrics & Gynecology at MacDonald Women’s Hospital; &
Associate Professor at Case Western Reserve University School of Medicine. He has been
recognized as one of the best physicians in his field, receiving a variety of “Top Doctor” &
“Top Women’s Doctor in America” citations. He is active in clinical research at University
Hospitals & the Case Comprehensive Cancer Center. He has extensive experience in the
design & conduct of human subject clinical trials, & holds leadership positions in the NCI
sponsored Gynecologic Oncology Group & the Society of Gynecologic Oncologists. He serves
as a peer reviewer for major publications in the field: Obstetrics & Gynecology, Gynecologic
Oncology, Cancer, International Journal of Gynecological Cancer, The Lancet, & Clinical
Cancer Research.
Dr. Waggoner will assist Dr. Gorodeski & the Company’s research teams in the
development, activation, conduct, & analysis of clinical trials designed to test the accuracy &
practicality for the CVX/GCI Assay, the Endometrial Cancer Screen, & the Drug Delivery
Device.
CEO Dr. David Weissberg stated: “We are very pleased to have Dr. Waggoner join our
Medical Advisory Board. His distinguished medical career has been dedicated to addressing
Gynecological Cancers. He has demonstrated consistent leadership in searching for new ways to
address & stop this specific women’s reproductive cancer. We believe Dr. Waggoner will be able
to make a substantial contribution in defining & focusing the development & clinical trials for
our bio-markers.”
Dr. George Gorodeski commented: “I am pleased with Dr. Waggoner joining the Medical
Advisory Board. Dr. Waggoner is now recognized as a leading expert in the filed of GYN-ONC,
& has demonstrated broad vision towards enhancing research & its application in fields that
CytoCore is developing. Undoubtedly through his assistance CytoCore will be able to better focus
its plans to meet the goals of developing cutting-edge biotechnology for early detection &
prevention of gynecological dysplasia & malignancies.”
Summary
In a news release dated 4/17/2006, CytoCore's CEO, Dr. David Weissberg stated: "I am
truly pleased to be able to report that we have been able to build off our year-end results to
increase our real momentum. We've been very successful in clearing up the liabilities & putting
the company on sound financial footing, we changed the company name to better reflect the
complete nature of the work being performed, & we settled an outstanding patent suit. The
continued positive progress made in the financial turn-around for the company in four months at
the end of 2005 paved the way during the first quarter of 2006 for the signing of a new strategic
relationship with University Hospitals of Cleveland & Dr. Gorodeski, & the licensing of the two
new products that enhance the InPath System. The power, impact, & opportunity this new
relationship & these new products represent for the company & the InPath System can hardly be
overstated.
"The Company formed a new research relationship with UHC & Dr. Gorodeski. With Dr.
Gorodeski's guidance, we will shortly begin the research efforts on our new products at UHC's
Clinical Research facility. Through a technology transfer agreement with UHC & Dr.
Gorodeski, the company licensed two new products:
"The first is a distinctive new cancer bio-marker, P2X7 that expands the InPath System
providing improved screening capability for both Cervical & Uterine cancers. The company is
going to pursue early development of this new bio-marker as a uterine cancer screen, which it
believes can be brought to market quickly - within 12 months. The opportunity is very large, as
there is no cancer screen available at this time for uterine cancer.
"The second product is a unique new Drug Delivery System that will offer the physician for
the first time the ability to therapeutically treat cervical lesions. The cost of treatment for the
10%positive or questionable Pap tests & the attendant cervical lesions is estimated at $3
billion/year with only one option at this time - surgery. The opportunity for this product is
significant indeed.
"We continue to expand our scientific capabilities by adding a gifted gynecologic cancer
researcher in Dr. Steven Waggoner to our Medical Advisory Board.
"The Company last week secured a major new round of institutional equity financing which
allows us to rapidly deploy a number of important development projects.
"The prototype for the e2 Collector has been successfully developed & tested, making this
product ready for manufacturing. The Collector will shortly be put into the final premanufacturing engineering phase - tooling. Early production runs will begin in 5-6 months.
"We expect to begin confirmation lab testing of the new bio-marker as an Endometrial Cancer
Screen, prior to an FDA trial. This cancer screen can be offered to the market without the
necessity of the AIPS system, which means sooner. At a later date, the AIPS can be brought
along as a Phase II enhancement to the Screen test.
"Tests will begin this quarter on the CVX Cocktail with the new marker combination. The
AIPS development program is moving forward toward late summer completion with early testing
expected by end of Q2. At that point, the process of customizing the AIPS to fit the CVX cocktail
with the new bio-marker will begin.
"This is a very exciting time for this company. In a short period of time & with limited
resources, we have truly turned the company around. Now with the expanded
product opportunities & the financial resources, we expect to again increase the momentum &
pace of development.
"As we look toward the coming year, it is fair to say that we could not be better positioned.
With the major advertising dollars currently being spent to focus attention on the importance of
the HPV screening test & the major ad dollars that soon will be spent by Merck in support of
their new HPV vaccine, we expect these campaigns will bring lots & lots of investor attention &
interest to companies in our sector. CytoCore's InPath System is so far advanced from the
competition, & offers such significant improvement to each phase of the Pap test with component
products so close to the market, we believe we will begin to attract the deserved attention of the
investment community at large. I am personally very excited about our prospects for the next
year & look forward to reporting our progress to you."
A CytoCore Advantage
With healthcare costs spiraling higher and higher, a shift is occurring nationally in the
thinking about the application of technology in healthcare. Many studies have shown that 7080% of a person’s entire healthcare expenditures over their whole life occur in the last four to
six months of life. As a result, more & more attention is being given to preventative medicine.
It is far better to catch the disease condition early before it gets out of hand & becomes a killer
disease.
As part of this shift in emphasis, the FDA recently announced that 60% of its approvals in
the coming period would be for “diagnostic related products.” These bio-molecular
screening, diagnostic, & treatment products are being developed to catch disease states early
so they can be dealt with before they become life threatening where healthcare costs
skyrocket.
CytoCore products are being designed to extend the reach of these screening & diagnostic
products into overseas markets (China, India, ASEAN, Latin America, Africa, & the Middle
East) where they do not have adequate laboratory infrastructures to accommodate such stateof-the-art testing.
Financial Status
On 4/17/2006, CytoCore announced its 2005 year-end financial results. The company
continues to increase its positive financial momentum with significant improvement in
operating results along with the recent announcement of new equity capital to provide for the
launch & development of new products.
CytoCore significantly reduced its operating loss before interest & dividends for the
12/2005 quarter & 2005 fiscal year. The loss for the 12/2005 quarter was $68,000, a 92%
reduction from the $924 thousand loss for the 12/2004 quarter. The 2005 fiscal year loss
before interest was $1.15 million, a 75% reduction from the $4.724 million loss for fiscal year
2004.
Overall, the Company reports a net loss of $4.346 million or ($0.04) per share for 2005, a
70% reduction from the $14.601 million & ($0.19) per share loss for 2004. Of the 2005 loss,
60% or $2.673 million is for the non-cash expense of the unamortized note discount incurred
with the conversion of notes to equity. As further evidence of the effectiveness of the turnaround, new management has reduced the operating loss before interest & preferred
dividends by 99% to $20,000 cumulative for the 3rd & 4th quarters of 2005, compared to an
operating loss before interest & preferred dividends of $1.130 million for the first six months
of 2005, & $4.724 million for 3rd & 4th quarters 2004.
Through 2006, the company will continue to reduce debt by converting note holders to
equity & settling with vendors on reduced terms. The full impact of discounts from
settlements negotiated in 2005 will not be realized until the settlements are fully paid.
As previously announced, the new equity capital obtained from institutional investors will
provide for the launch of the E2 Collector; development & commencement of patient trials for
the cervical & endometrial cancer markers, & the cervical drug delivery device.
According to CFO Robert F. McCullough Jr., "Most of the accrued liabilities & accounts
payable should be settled in 2006 at amounts well below the amounts currently carried in the
financial statements. We also look forward to strengthening the capital structure by converting
much of the remaining notes & preferred stock to equity during Q2 2006. By significantly
reducing the operating loss, we expect that most of the company's resources in the foreseeable
future will be focused to move the company forward; enhancing shareholder value through
multiple product development programs, & product sales for the Collector, AIPS & Endometrial
Cancer Screen."
Recent News
5/1/2006 -- CytoCore announced that the first paper on the workings of the P2X7 BioMarker submitted by Dr. George Gorodeski, the inventor, was accepted for publication by the
Journal of Biological Chemistry. The full paper can be found at
www.jbc.org/cgi/reprint/M602999200v1
Dr. Gorodeski is in the process of submitting another paper on the clinical implications of
this Bio-Marker. CytoCore has an unrestricted license to the P2X7 marker which the
Company licensed this past February from University Hospitals Cleveland & Dr. Gorodeski.
4/27/2006 -- CytoCore announced the engagement of Dr. Jorge A. Leon, Ph.D., as a member
of the Medical Advisory Board & his company, Leomics Associates, as consultants to
CytoCore.
Dr. Leon has a Ph.D. in Cellular & Molecular Biology. He was one of the founders of the
Molecular Diagnostic and Applied Genomics business at Quest Diagnostics where, as their VP
of applied genomics, he helped build & drove the strategy for Quest Diagnostics' Molecular
Diagnostics business, now the largest in the country. Dr Leon is recognized internationally
within the investment & scientific communities as an industry leader for molecular
diagnostics. Presently he is founder & President of Leomics Associates, Inc., a consulting
company that develops diagnostic strategies for companies that want to enter the diagnostics
space. He has over 20 years of experience in evaluating, developing, & commercializing new
technologies & scientific innovations into successful diagnostic products. He is the holder of
several patents, has been published extensively, & serves on the Boards of various leading
edge technology companies.
Dr. Weissberg said: “We are delighted in this new relationship with Dr. Jorge Leon &
Leomics. Dr. Leon brings a depth of real world business experience & credibility in the
commercialization of new diagnostic products. Dr. Leon’s experience, business background &
contacts should help inform & guide CytoCore’s strategic decisions & the current plans for each
of CCI’s products. With the e2 Collector ready for pre-manufacturing tooling, Dr. Leon will be
able to assist us in meeting appropriate distribution partners to bring the Collector to the widest
audience of users. Given Dr. Leon’s extensive experience & perspective in the Biomolecular &
Diagnostic sectors, we anticipate his support & guidance with the introduction of the P2X7
biomarker to the cervical & endometrial cancer screening marketplace. Dr. Leon is familiar with
CytoCore’s technology portfolio, and he is ready to help bring these valuable & lifesaving
products to the marketplace.”
Dr. Leon commented, "I am very excited with the opportunity to participate on CytoCore's
Medical Advisory Board. I've been watching this technology for some time. The science from
Dr. Gorodeski’s lab is scientifically sound, published in first tier peer reviewed journals, & has
great potential in unmet applications in diagnostics & drug delivery. I am especially excited
about the application of CytoCore’s technology platform & biomarkers in developing countries
where the conventional, more expensive diagnostic methods for cervical cancer & other cancers
are not fully implemented or effective. If the P2X7 marker proves itself with further testing to be
consistently accurate with the initial lab tests, this marker will be a major advancement in
screening for cervical & endometrial cancer. I am looking forward to contributing to the
development & commercialization of CytoCore's unique mix of life saving medical technologies."
New Funding
On 4/11/2006, CytoCore announced it had secured in excess of $1 million in new equity
financing from institutional sources through the issuance of common stock at current market
prices. The funding will be used to immediately implement key aspects of its product
development plans.
"With this new funding CytoCore will be putting a number of key programs into motion,"
said CEO David Weissberg. "They include hiring key personal for our research laboratory with
Dr. Gorodeski & our product development laboratory with the AIPS project in Chicago, putting
the e2 Collector into manufacturing development, & bringing together resources & people to
develop the strategic distribution strategy for the Collector. We expect to have a string of positive
developments to announce over the coming months."
A representative for one of the institutional investors stated: "I have been following this
company for a number of years. The progress made under the current management team with
the turn-around is very positive. I believe the company is substantially undervalued even when
valuing only its near term commercial opportunity with the e2-collector. Considering the longerterm commercial opportunity, with the bio-markers & the automated microscope, the current
market valuation could in hind-sight prove to be irrationally low, bearing in mind that more than
$40 million has been invested in the company to date to bring MCDG's technologies to the
market."
Financing & Projections
On April 11, 2006 the Company announced it secured in excess of $1 million in new
financing. That is a major milestone toward profitability. From a Company business plan
document (March 2006), the current round of capital investment will be used to:
-
complete the financial restructuring;
-
it will bring the e2 Collector into production, marketing and sales;
-
it will forward the development & engineering on the P2X7 bio-marker as an
Endometrial Cancer Screening test prior to entering trials.
-
it will move the AIPS development project toward completion;
-
it will move the development & integration of the CVX/GCI Cocktail with the AIPS
Platform ready for clinical Trials,
-
it will begin the development of the prototype handle and patch for the Drug
Delivery System, & set up the parameters for the trials.
The following projections are from the same document.
As these numbers suggest, if the Company is successful in getting to cash flow break even
during 2007, the revenue, earnings, & stock appreciation potential becomes very significant
over the next two to four years.
Our Opinion
MCDG has a world-class technology & scientific team. It has put a first-class management
team in place. Its exciting turn-around is virtually complete. We suggest that you do your
due diligence on this one -- we predict that you will be impressed with what is happening &
with its appreciation opportunity. It is our opinion that this emerging situation has a 90%+
probability of success. It is certainly suitable for investors who accept high risk situations,
but in our opinion it is also suitable for those who like the potential but want to invest in
moderate risk situations. We like the fact that the company is now adequately funded. These
funds should provide the flexibility to get each of the key projects well along prior to the
necessity of having another financing. Because of the approximately $40million in prior
investments, CytoCore requires minimal current investment to bring its initial products to
market & achieve a cash flow break even.
Equally important is the probability that if another financing is needed in the future, the
funding probably will be brought in at a higher price per share with the attendant reduction
in dilution. We are rather enthusiastic about the future of this company & definitely like its
prospects over the next 24 to 36 months. We believe it could comfortably produce a 10x
multiple on the current price over that time period. The upside is substantial enough here to
recommend that if you like the company’s prospects, you consider building a position in this
price area, & then as more of the essential developmental milestones are achieved along the
way toward cash flow break even, add to your position, averaging up. In this manner, you
can put more funds at work as the risk of success grows stronger. Check www.MolecularDx.com.
Contact
CytoCore is located at 414 North Orleans Street, Suite 502, Chicago, IL 60610. Phone: 312222-9550 -- Fax: 312-222-9580 -- www.molecular-dx.com -- Call Gene Martineau at 212-3481852 -- ebm@interport.net
Disclaimer/Disclosure:
The public companies covered by Corporate Profiles in the "Special
Situation" section of www.WallStreetCorner.com normally pay an Annual fee of US$9,500 cash for such
coverage. In the case of MCDG, we agreed to permit the company to retain us for a six-month period. The
company paid us $3,000 cash & has agreed to send us $3,000 worth of their restricted shares at the bid price
at 3/30/2006. Information displayed by WallStreetCorner does not constitute an offer to buy, sell, or trade a
security of any kind, including stock. Neither Larry Oakley, Rosanne Oakley, nor WallStreetCorner.com,
Inc. recommend that any person, institution, or other entity make any decisions or form any opinions, etc.
based on the information on this site. All visitors to this site are urged to consult a qualified financial
professional before taking any actions in regards to buying, selling, or trading securities (stocks or other
forms of equity). Companies covered in Conservative Speculator, a newsletter accessed from
WallStreetCorner, or in any of Larry Oakley's editorial venues do not pay for such editorial coverage; the
companies Larry covers editorially have never, do not now, & never will be charged for editorial coverage.
The companies that pay the current US$9,500 annual fee or any portion thereof are told this verbally, & their
Web Participation Contract contains essentially the following clause: "It is understood that editorial
coverage by Lawrence C. Oakley in Conservative Speculator; his Opinion, Stock Pick, Comment, Bold
Ventures, & other columns; contributions to national media; radio/TV interviews; or speaking engagements,
have always been, are now, & will always be without cost, & that such editorial coverage is not a part of this
contract."
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
Statements in
this document looking forward in time involve risks & uncertainties, & therefore actual results may be
materially different than those implied in the text hereof. Factors that could cause actual results to differ
include activity levels in the securities markets & other risk factors such as customer order rates,
cancellations, late delivery of customer components, late system delivery, production delays, dependence
upon certain customers, dependencies upon key executives, competition, product liability risk, control by
management, actions by the client company’s management, & other risks detailed in the applicable U.S.
Securities & Exchange Commission requirements.